In fact, pioglitazone can slow down the progression to type 2 diabetes when used in IGT patient [27], while both GLP-1 mimetics and DPP-4 inhibitors improve β-cell function measured by HOMA-β [30]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.